secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bellerophon Therapeutics, Inc. (—)
CIK:        0001600132
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001104659-23-076314
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Bellerophon ends Phase 3 REBUILD trial, lays off substantially all staff, explores strategic alternatives
--------------------------------------------------------------------------------

- Phase 3 REBUILD trial of INOpulse for fibrotic ILD failed primary endpoint; secondary endpoints not statistically significant.
- Company terminates trial and withdraws patients from all INOpulse programs.
- Reduction-in-force of substantially all employees, including CEO Peter Fernandes and other executives; departures effective July 15, 2023.
- Severance and termination costs estimated at ~$2M, to be recorded in Q2 2023.
- Board to explore strategic alternatives including merger, sale, or liquidation; no set timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600132/000110465923076314/0001104659-23-076314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600132/000110465923076314/tm2320161d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-076314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer